ENHERTU + Pertuzumab Shows PFS Gain in HER2+ Breast Cancer
Positive topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and...